Other Events ·
AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan) in…
AZNAstrazeneca PLC
AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. This approval is based on the DESTINY-Breast09 Phase III trial, which demonstrated that the regimen reduced the risk of disease progression or death by 44% compared to standard care (THP), with median progression-free survival exceeding three years versus approximately two years. Following this regulatory milestone, AstraZeneca is obligated to pay Daiichi Sankyo a $100 million milestone payment. The company operates in the global biopharmaceutical industry, focusing on the discovery and commercialization of prescription medicines.